UBS Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-87,637
| Closed | -$200K | – | 10342 |
|
|
2024
Q2 | $200K | Buy |
87,637
+87,329
| +28,354% | +$334K | ﹤0.01% | 5659 |
|
|
2024
Q1 | $1.33K | Sell |
308
-2,872
| -90% | -$10K | ﹤0.01% | 8159 |
|
|
2023
Q4 | $9.7K | Buy |
3,180
+2,967
| +1,393% | +$5.58K | ﹤0.01% | 7474 |
|
|
2023
Q3 | $307 | Sell |
213
-2,501
| -92% | -$4.84K | ﹤0.01% | 8597 |
|
|
2023
Q2 | $6.76K | Sell |
2,714
-3,587
| -57% | -$9.8K | ﹤0.01% | 7340 |
|
|
2023
Q1 | $16.9K | Sell |
6,301
-1,682
| -21% | -$8.08K | ﹤0.01% | 7207 |
|
|
2022
Q4 | $43.3K | Sell |
7,983
-48,000
| -86% | -$402K | ﹤0.01% | 6899 |
|
|
2022
Q3 | $700K | Buy |
55,983
+55,770
| +26,183% | +$637K | ﹤0.01% | 4050 |
|
|
2022
Q2 | $1K | Sell |
213
-222,706
| -100% | -$1.23M | ﹤0.01% | 10036 |
|
|
2022
Q1 | $1.69M | Sell |
222,919
-34,800
| -14% | -$330K | ﹤0.01% | 3597 |
|
|
2021
Q4 | $2.63M | Buy |
257,719
+137,157
| +114% | +$1.75M | ﹤0.01% | 3490 |
|
|
2021
Q3 | $1.62M | Buy |
120,562
+105,274
| +689% | +$1.72M | ﹤0.01% | 3766 |
|
|
2021
Q2 | $335K | Sell |
15,288
-51,183
| -77% | -$1.14M | ﹤0.01% | 5009 |
|
|
2021
Q1 | $1.6M | Buy |
66,471
+66,258
| +31,107% | +$1.54M | ﹤0.01% | 3788 |
|
|
2020
Q4 | $4K | Sell |
213
-5,000
| -96% | -$74.7K | ﹤0.01% | 7940 |
|
|
2020
Q3 | $60K | Buy |
5,213
+3,648
| +233% | +$60.2K | ﹤0.01% | 5512 |
|
|
2020
Q2 | $38K | Sell |
1,565
-9,161
| -85% | -$151K | ﹤0.01% | 6106 |
|
|
2020
Q1 | $118K | Sell |
10,726
-16,684
| -61% | -$312K | ﹤0.01% | 5145 |
|
|
2019
Q4 | $725K | Sell |
27,410
-39,261
| -59% | -$918K | ﹤0.01% | 4510 |
|
|
2019
Q3 | $1.52M | Buy |
66,671
+49,598
| +291% | +$1.56M | ﹤0.01% | 3575 |
|
|
2019
Q2 | $524K | Buy |
17,073
+16,360
| +2,295% | +$344K | ﹤0.01% | 4258 |
|
|
2019
Q1 | $12K | Sell |
713
-93,428
| -99% | -$1.77M | ﹤0.01% | 6703 |
|
|
2018
Q4 | $1.8M | Buy |
94,141
+86,380
| +1,113% | +$3.24M | ﹤0.01% | 3134 |
|
|
2018
Q3 | $406K | Buy |
7,761
+5,568
| +254% | +$304K | ﹤0.01% | 4558 |
|
|
2018
Q2 | $95K | Buy |
2,193
+1,093
| +99% | +$46.8K | ﹤0.01% | 5483 |
|
|
2018
Q1 | $40K | Sell |
1,100
-254
| -19% | -$6.78K | ﹤0.01% | 5887 |
|
|
2017
Q4 | $27K | Buy |
1,354
+954
| +239% | +$20.5K | ﹤0.01% | 6334 |
|
|
2017
Q3 | $10K | Sell |
400
-495
| -55% | -$9.14K | ﹤0.01% | 6901 |
|
|
2017
Q2 | $15K | Buy |
+895
| New | +$15.7K | ﹤0.01% | 6501 |
|
UBS Group's GTHX Position: Q3 2024 in Review
UBS Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 87,637 shares — an estimated $200K sold.
UBS Group first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $2.63M in Q4 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- UBS Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 87,637 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $200K.
- UBS Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- UBS Group's G1 Therapeutics, Inc. Common Stock position peaked at $2.63M in Q4 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.